Search

Your search keyword '"Schmitt, Nanni"' showing total 33 results

Search Constraints

Start Over You searched for: Author "Schmitt, Nanni" Remove constraint Author: "Schmitt, Nanni"
33 results on '"Schmitt, Nanni"'

Search Results

1. Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms

2. Instructive interaction between myelodysplastic hematopoiesis and the bone marrow microenvironment at the single-cell level

3. Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies

4. Instructive interaction between myelodysplastic hematopoiesis and the bone marrow microenvironment at single cell level

5. Humanized three-dimensional scaffold xenotransplantation models for myelodysplastic syndromes

6. Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes

9. Significant improvement of bone marrow-derived MSC expansion from MDS patients by defined xeno-free medium

10. In Silico Pan-Cancer Analysis Reveals Prognostic Role of the Erythroferrone (ERFE) Gene in Human Malignancies

11. Direct Comparison of NSG and NBSGW Mice for MDS Patient-Derived Xenograft Models

12. The Novel Bispecific Innate Cell Engager (ICE®) AFM28 Efficiently Directs Allogeneic NK Cells to CD123+ Leukemic Stem- and Progenitor Cells in AML

13. Inhibition of Lysyl Oxidases Synergizes with 5-Azacytidine to Restore Erythropoiesis in Myeloid Neoplasms

14. ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes

15. Abstract 6257: Mutations in the ASXL1 and ZRSR2 genes are associated with the response to the combination of alvocidib and 5-azacytidine in higher-risk myelodysplastic syndromes

17. Preclinical Assessment of Alvocidib in Combination with 5-Azacytidine in High-Risk Myelodysplastic Syndromes

18. Mesenchymal Stromal Cells (MSCs) from Myelodysplastic Syndromes (MDS) Are Not Clonally Mutated I n Vivo

19. AFM28, a Novel Bispecific Innate Cell Engager (ICE ®), Designed to Selectively Re-Direct NK Cell Lysis to CD123+ Leukemic Cells in Acute Myeloid Leukemia and Myelodysplastic Syndrome

20. Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes

21. High erythroferrone expression in CD71+ erythroid progenitors predicts superior survival in myelodysplastic syndromes

23. Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations

24. R-Loops-Induced ATR Signaling As a Potential Therapeutic Target in Myelodysplastic Syndrome

25. Comparison of Four Different Humanized Hematopoietic Niche Xenotransplantation Methods to Engraft Myelodysplastic Syndromes (MDS)

26. Placebo Controlled Functional Analysis of Eltrombopag in a Preclinical Xenograft Model of Myelodysplastic Syndromes (MDS)

27. High erythroferrone expression in CD71+ erythroid progenitors predicts superior survival in myelodysplastic syndromes.

28. Instructive Interaction between Myelodysplastic Hematopoiesis and the Bone Marrow Microenvironment at Single Cell Level

29. ASXL1Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes

30. Comparative analysis of clonal hematopoiesis of multipotent stem cells in healthy elderly in blood and bone marrow.

31. ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms.

32. Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations.

33. High erythroferrone expression in CD71 + erythroid progenitors predicts superior survival in myelodysplastic syndromes.

Catalog

Books, media, physical & digital resources